Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03630770 · ClinicalTrials.gov registry record · Phase 1

Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida

A Phase 1 study of Premature Infant and Candida Infection, sponsored by Joseph Bliss.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT03630770 is a Phase 1 study of Premature Infant and Candida Infection that has completed, run by Joseph Bliss. The registered enrollment target is 12 participants, below the 289-participant average among 9 other Premature Infant trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03630770, a Phase 1 study of Premature Infant and Candida Infection, has completed, sponsored by Joseph Bliss.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This study evaluates whether adding a dietary supplement similar to coconut oil (MCT oil) to feedings in premature infants will reduce the amount of yeast (Candida) detectable in their stool. Infants who have Candida in their stool are eligible to participate. Half of the enrolled infants will have additional MCT oil added to their feedings and half will not.

Interventions

  • DRUG Medium-Chain Triglyceride (MCT) Oil

Study Locations (1)

Rhode Island

  • Women & Infants Hospital of Rhode Island - Providence

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2014-06-05
Est. Completion 2021-11-02
Phase Phase 1

Sponsor

Joseph Bliss

1 total trials

What the Registry Record Tells You About NCT03630770

The ClinicalTrials.gov registry entry for NCT03630770 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 289-participant average among 9 other Premature Infant trials with a reported enrollment target (96% lower). The listed sponsor is Joseph Bliss, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Premature Infant appearing as the primary indexed condition, and to 1 intervention - of which Medium-Chain Triglyceride (MCT) Oil is the first listed.

NCT03630770 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT03630770 about?

NCT03630770 is a clinical study titled "Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida". This study evaluates whether adding a dietary supplement similar to coconut oil (MCT oil) to feedings in premature infants will reduce the amount of yeast (Candida) detectable in their stool. Infants who have Candida in their stool are eligible to participate. Half of the enrolled infants will have ...

What is the current status of trial NCT03630770?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-06-05. Estimated completion is 2021-11-02.

What conditions does trial NCT03630770 study?

This clinical trial studies the following conditions: Premature Infant, Candida Infection.

What interventions are being tested in trial NCT03630770?

The interventions under investigation include: Medium-Chain Triglyceride (MCT) Oil (DRUG).

Who is sponsoring clinical trial NCT03630770?

This trial is sponsored by Joseph Bliss, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03630770 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Premature Infant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.